Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc

Bullboard Posts

Comment by Divineincon Feb 06, 2020 10:38am

91 Views

Post# 30651609

RE:RE:RE:Attention NEW Investors ! - Deal coming - Read up !

Looking4Doubles - (2/6/2020 10:35:25 AM)
RE:RE:Attention NEW Investors ! - Deal coming - Read up !

Looking4Doubles wrote:

Looking4Doubles wrote:
Huffington Post lists Kalyetra in top 4 medical cannabis companies

Kalyetera receives unsolicited inquiries

Stellar phase 2 results

The next GW Pharma

More positive news on Kalyetras test results

” in the Company’s most recent MD&A) to December 15, 2019, which maturity date may be further extended to March 15, 2020 in the event that the Company enters into a term sheet providing for the license or disposition of the Company’s GVHD program or the sale or merger of the Company by December 15, 2019. In connection with the extension of the maturity date of the promissory note, the Company amended the milestone payment schedule under the share purchase agreement with the former shareholders of Talent

and then:

Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the "Company" or "Kalytera") today announced that, in accordance with the previously announced agreement between the Company and the former shareholders of the Company’s subsidiary, Talent Biotechs Ltd., the Company has agreed with the note holder of the secured promissory note in the approximate amount of USD $2 million in favor of such shareholders to extend the maturity date of the note until March 15, 2020.

BUT . . that's only supposed to happen if there is a term sheet ! ! HINT HINT HINT ! ! !

Add the patents and we have a home run for investors and UNLIMITED LOSSES FOR THE SHORTS LMAO ! ! !

Report and ignore the basher!!! Very good thing is coming!